Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17386334 | 1.00 | MAOB (0.54) | MAOBFFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3661378 | 0.88 | MAOB (0.52) | MAOBFFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3661376 | 0.88 | MAOB (0.52) | MAOBFFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3661373 | 0.88 | MAOB (0.52) | MAOBFFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17386188 | 0.88 | MAOB (0.52) | MAOBFFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3661368 | 0.88 | MAOB (0.52) | MAOBFFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17386186 | 0.88 | MAOB (0.52) | MAOBFFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17386237 | 0.86 | MAOB (0.51) | MAOBFFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18828172 | 0.86 | MAOB (0.51) | MAOBFFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17386239 | 0.86 | MAOB (0.51) | MAOBFFAR1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108017603-B | Tricyclic compounds and uses thereof | 株式会社蒂奥姆生物 | 2021-07-23 | — | — | CN | disclosed |
| EP-2963027-B1 | TRICYCLIC COMPOUND AND USE THEREOF | TIUMBIO CO LTD (KR) | 2018-12-26 | — | — | EP | disclosed |
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
| EP-2963027-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK Chemicals Co., Ltd. (KR) | 2016-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | GPR65, GPR119, GPR35 | MAOB 3145/4885FFAR1 22/4885NPC1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.